Cancer 1st Line Tx Flashcards
Breast:
- ER/PR(+)
- HER2(-)
RS <26: EndoTx
- PreMeno: Tx5yr +/- OS or AIx5yr + OS (Still PreMeno: Tx5yr or stop // Now PostMeno: AI or T x5yr)
- PostMeno: AIx5yr then AIx5yr OR Tx2-3yr then AIx5yr
RS >26: ChemoTx then EndoTx
- Dose Dense AC then Paclitaxel or TC (Docetaxel + Cytoxin)
Breast:
- ER/PR(+)
- HER2(+)
Tumor <0.5cm: adju EndoTx (PreMeno: Tx5yr +/- OS or AIx5yr + OS (Still PreMeno: Tx5yr or stop // Now PostMeno: AI or T x5yr)
- PostMeno: AIx5yr then AIx5yr OR Tx2-3yr then AIx5yr) +/- Chemo +HER2Tx (APT (adju Paclitaxel +Trastuzumab) or TCH+/- P (Docetaxel + Carbo + Trastu +/- Pertuzumab)
Breast:
- TNBC
Pembrolizumab + Paclitaxel + Carbo then Prembro + Doxorubucin + Cytoxin
Breast:
- Meta-HER2(+)
1st: Trastuzumab + Pertuz + Docetaxel
2nd: Trastu-Deruxtecan
Breast:
- Meta-HER2(-)
1st: AI + CDK4/6-i (Palbociclib)
2nd: Fulvestrant + CDK4/6-i
Prostate:
- Localized
ADT (GNRH agonist) +/- Anti-androgen Tx (Abiraterone or Enzalutamide)
Prostate:
- M0HSPC
GNHR agonist +/- ADT
Prostate:
- M0CRPC
Continue ADT and add ONE of: Enzalutamide, Apalutamide, Darolutamide
Prostate:
- M1HSPC
- LOW Volume: ADT or ADT + Abiraterone and Prednisone, Enzalutamide, or Apalutamide
- HIGH Volume: Docetaxel + ADT +/- Abiraterone or Daralutamide
Prostate:
- M1CRPC
1st: Docetaxel + Prednisone
2nd: Cabazitaxel + Prednisone
- IF PSMA(+) use: Pluvicto
Lung:
- SCLC
- Limited: Radiation + EP or EC (Etop, cisP/Carbo)
- Extensive: EC + Atezolizumab or Durvalumab
Lung:
- NSCLC (Resectable)
- Non-Squamous: Cisplatin + Pemetrexed (or Carbo)
- Squamous: Cisplatin + Gemcitabine or Docetaxel (or Carbo)
Lung:
- NSCLC (UnResectable)
- Non-Squamous: Carbo/Cis + Pemetrexed OR Cis + Etop
- Squamous: Paclitaxel + Carbo OR Cis + Etop
(If any Tx not working: Durvalumab x1yr)
Lung: NSCLC
- Metastatic (Mutations Present)
Osimertinib (EGFR), Dabraf/Tramet (BRAF), Sotoasib (K-RAS)
Lung: NSCLC
- Metastatic (NO mutations)
- Non-squamous: Carbo + Pemetrexed + Pembrolizumab
- Squamous: Carbo + Prembrolizumab + Paclitaxel